5 Value Stocks In The Healthcare Sector

What are Value Stocks?

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:

1. Cooper Companies COO - P/E: 8.67
2. Innoviva INVA - P/E: 5.93
3. Catalyst Pharmaceuticals CPRX - P/E: 8.22
4. Triple-S Management GTS - P/E: 4.6
5. InVivo Therapeutics Hldg NVIV - P/E: 0.62

Cooper Companies saw an increase in earnings per share from 3.17 in Q1 to 3.38 now. Its most recent dividend yield is at 0.02%, which has ('', 'not changed') by 0.0% from 0.02% in the previous quarter.

This quarter, Innoviva experienced an increase in earnings per share, which was 0.48 in Q4 and is now 0.84. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Most recently, Catalyst Pharmaceuticals reported earnings per share at 0.07, whereas in Q4 earnings per share sat at 0.11. Catalyst Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Triple-S Management has reported Q1 earnings per share at 0.67, which has increased by 272.22% compared to Q4, which was 0.18. Triple-S Management does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

InVivo Therapeutics Hldg has reported Q1 earnings per share at -0.08, which has decreased by 111.59% compared to Q4, which was 0.69. InVivo Therapeutics Hldg does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.